Potentiation of tumor necrosis factor-α expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway

Biochemical Pharmacology

Volumn 66, Issue 1, 2003, Pages 149-156

  Hwang, Tsong Long ^a   Wu, Chin Chung ^b   Guh, Jih Hwa ^c   Teng, Che Ming ^c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Alveolar macrophage; Cyclic GMP; NR 8383; TNF; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 8 BROMO CYCLIC AMP; 8 BROMO CYCLIC GMP; BUCLADESINE; CYCLIC AMP; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC GMP DERIVATIVE; CYCLOHEXIMIDE; DIBUTYRYL CYCLIC GMP; FORSKOLIN; GAMMA INTERFERON; GENISTEIN; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; INDOMETACIN; KT 5823; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME ASSAY; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS REGULATION; RAT; TIME; TRANSCRIPTION REGULATION;

EID: 0037667865     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00202-8     Document Type: Article

References (36)

1. Ko F.N., Wu C.C., Kuo S.C., Lee F.Y., Teng C.M. YC-1, a novel activator of platelet guanylate cyclase. Blood. 84:1994;4226-4233.
2. Wu C.C., Ko F.N., Kuo S.C., Lee F.Y., Teng C.M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 116:1995;1973-1978.
3. Teng C.M., Wu C.C., Ko F.N., Lee F.Y., Kuo S.C. YC-1 a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur. J. Pharmacol. 320:1997;161-166.
4. Mülsch A., Bauersachs J., Schäfer A., Stasch J.P., Kast R., Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. 120:1997;681-689.
5. Wegener J.W., Nawrath H. Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle. Eur. J. Pharmacol. 323:1997;89-91.
6. Tulis D.A., Durante W., Peyton K.J., Chapman G.B. YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem. Biophys. Res. Commun. 279:2000;646-652.
7. Friebe A., Schultz G., Koesling D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J. 15:1996;6863-6868.
8. Friebe A., Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol. Pharmacol. 53:1998;123-127.
9. Stone J.R., Marletta M.A. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chem. Biol. 5:1998;255-261.
10. Sharma V.S., Magde D., Kharitonov V.G., Koesling D. Soluble guanylate cyclase: effect of YC-1 on ligation kinetics with carbon monoxide. Biochem. Biophys. Res. Commun. 254:1999;188-191.
11. Denninger J.W., Schelvis J.P., Brandish P.E., Zhao Y., Babcock G.T., Marletta M.A. Interaction of soluble guanylate cyclase with YC-1: kinetic and resonance Raman studies. Biochemistry. 39:2000;4191-4198.
12. Hwang T.L., Wu C.C., Teng C.M. YC-1 potentiates nitric oxide-induced relaxation in guinea-pig trachea. Br. J. Pharmacol. 128:1999;577-584.
13. McLaughlin B.E., Chretien M.L., Choi C., Brien J.F., Nakatsu K., Marks G.S. Potentiation of carbon monoxide-induced relaxation of rat aorta by YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole]. Can. J. Physiol. Pharmacol. 78:2000;343-349.
14. Friebe A., Mullershausen F., Smolenski A., Walter U., Schultz G., Koesling D. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol. Pharmacol. 54:1998;962-967.
15. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide - physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:1991;109-142.
16. Garthwaite J., Boulton C.L. Nitric oxide signaling in the central nervous system. Annu. Rev. Physiol. 57:1995;683-706.
17. 2+/calmodulin in RAW 264.7 cells. Biochim. Biophys. Acta. 1539:2001;101-113.
18. 2 and cyclic nucleotides. J. Immunol. 141:1998;2388-2393.
19. Arias-Diaz J., Vara E., Garcia C., Villa N., Balibrea J.L. Evidence for a cyclic guanosine monophosphate-dependent, carbon monoxide-mediated, signaling system in the regulation of TNFα production by human pulmonary macrophages. Arch. Surg. 130:1995;1287-1293.
20. Kiemer A.K., Hartung T., Vollmar A.M. cGMP-mediated inhibition of TNF-α production by the atrial natriuretic peptide in murine macrophages. J. Immunol. 165:2000;175-181.
21. Marino M.W., Dunn A., Grail D., Inglese M., Noguchi Y., Richards E., Jungbluth A., Wada H., Moore M., Williamson B., Basu S., Old L.J. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 94:1997;8093-8098.
22. Yoshina S., Kuo S.C. Studies on heterocyclic compounds. XXXV. Synthesis of flu[3,3-C]pyrazole derivatives. (2) Electrophilic substitution of 1,3-diphenylfuro[3,2-C]pyrazole. Yakugaku Zasshi. 98:1978;204.
23. Wang J.P., Chang L.C., Raung S.L., Hsu M.F., Huang L.J., Kuo S.C. Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cyclic GMP-dependent and -independent mechanisms. Biochem. Pharmacol. 63:2002;577-585.
24. Wantanable S., Kobayshi T., Okuyama H. Regulation of lipopolysaccharide-induced tumor necrosis factor alpha production by endogenous prostaglandin E2 in rat resident and thioglycollate-elicited macrophages. J. Lipid Mediat. Cell Signal. 10:1994;283-294.
25. Wu C.C., Ko F.N., Teng C.M. Inhibition of platelet adhesion to collagen by cGMP-elevating agents. Biochem. Biophys. Res. Commun. 231:1997;412-416.
26. Yu S.M., Cheng Z.J., Guh J.H., Lee F.Y., Kuo S.C. Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells. Biochem J. 306:1995;787-792.
27. Galle J., Zabel U., Hübner U., Hatzelmann A., Wagner B., Wanner C., Schmidt H.H.H.W. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br. J. Pharmacol. 127:1999;195-203.
28. Wegener J.W., Gath I., Forstermann U., Nawrath H. Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat. Br. J. Pharmacol. 122:1997;1523-1529.
29. 3 lactotrophs. Neuropharmacology. 39:2000;1788-1799.
30. Wohlfart P., Malinski T., Ruetten H., Schindler U., Linz W., Schoenafinger K., Strobel H., Wiemer G. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br. J. Pharmacol. 128:1999;1316-1322.
31. 2+ entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils. Biochem. Pharmacol. 62:2001;679-684.
32. Kiemer A.K., Vollmar A.M. Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide. J. Biol. Chem. 273:1998;13444-13451.
33. Hug H., Sarre T.F. Protein kinase C isoenzymes: divergence in signal transduction? Biochem. J. 291:1993;329-343.
34. Alessi D.R. The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1β (Rsk-2) and p70 S6 kinase. FEBS Lett. 402:1997;121-123.
35. Beltman J., McCormick F., Cook S.J. The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase. J. Biol. Chem. 271:1996;27018-27024.
36. Hers I., Tavare J.M., Denton R.M. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. 460:1999;433-436.